Live tape
Top 8, mentions 7d10,771GOOGL2,061 mentions▲ +0.04SNDK1,523 mentions▲ +0.11SPCX1,494 mentions▲ +0.08NBIS1,420 mentions▲ +0.09HTZ1,232 mentions▲ +0.10NVDA1,187 mentions▲ +0.08META1,015 mentions▲ +0.03MSFT839 mentions▲ +0.06

Equity · Healthcare

BBIO

BridgeBio Pharma, Inc. · NasdaqGS

$79.89 +0.04% 1D Finazon · prior-day close · Aug 17, 2026
Price · Chart
Our own end-of-day closes 61 sessions
$100 $60 20 May 17 Aug

The line runs $68.25 on 20 May through $79.89 on 17 August, on a scale from $60 to $100. Days the market did not trade hold the previous close, flat.

Track this symbol on TradingView

The chart above plots the price of BBIO over the range selected — one day to the full history — drawn by TradingView from their own data. Our own licensed end-of-day series holds 61 sessions over that window: $68.25 on 20 May 2026 through $79.89 on 17 August 2026.

Market cap $15.6B
52-week range $47 – $90
Avg volume 511.3K

Finazon · prior-day close · valuation computed from SEC EDGAR filings · as of Aug 18, 2026

BBIO insider trades

SEC Form 4 · last 90 days · newest reported trade 30 Jul 2026
Open-market buys 0
Open-market sells 11
Net sold $29.17M
Non-trade filings 18
Date Insider Type Shares Value
30 Jul 2026 Apuli Maricel Chief Accounting Officer Sell 2,000 $160K
09 Jul 2026 Cook Jennifer E. Director Sell 148,589 $13.16M
09 Jul 2026 Ellis Andrea Director Sell 17,167 $1.44M
24 Jun 2026 Cook Jennifer E. Director Sell 37,167 $2.60M
23 Jun 2026 Valantine Hannah Director Sell 2,196 $151K
23 Jun 2026 Cook Jennifer E. Director Sell 2,196 $151K
22 Jun 2026 Valantine Hannah Director Sell 2,808 $191K
15 Jun 2026 Cook Jennifer E. Director Sell 90,240 $6.01M
05 Jun 2026 Kumar Neil Chief Executive Officer Sell 31,563 $2.14M
04 Jun 2026 Kumar Neil Chief Executive Officer Sell 20,000 $1.35M
21 May 2026 Kumar Neil Chief Executive Officer Sell 26,103 $1.81M

Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.

Date Insider Type Shares Value
09 Jul 2026 Cook Jennifer E. Director Option exercise 148,589 $3.71M
09 Jul 2026 Ellis Andrea Director Option exercise 17,167 $288K
24 Jun 2026 Cook Jennifer E. Director Option exercise 37,167 $457K
22 Jun 2026 AGUIAR ERIC Director Award 3,990
22 Jun 2026 Satvat Ali J. Director Award 3,990
22 Jun 2026 Dachille Douglas A. Director Award 3,990
22 Jun 2026 MCCORMICK FRANK Director Award 3,990
22 Jun 2026 MOMTAZEE JAMES C Director Award 3,990
22 Jun 2026 Hassan Fred Director Award 3,990
22 Jun 2026 Ellis Andrea Director Award 3,990
22 Jun 2026 DANIELS RONALD J Director Award 3,990
22 Jun 2026 HOMCY CHARLES J Director Award 3,990

Showing the 12 most recent of 18 compensation filings in this window. The figures above count all of them.

BBIO reported financials

SEC EDGAR XBRL

BBIO reported revenue of $502.1M for the fiscal year ended 31 Dec 2025. Net income over the same period was −$724.9M.

Figure Reported Period
Revenue $502.1M 31 Dec 2025 fiscal year
Net income to common shareholders −$724.9M 31 Dec 2025 fiscal year
Diluted EPS −$3.78 31 Dec 2025 fiscal year
Total assets $1.2B 30 Jun 2026 at period end
Total equity −$2.5B 30 Jun 2026 at period end

Source: SEC EDGAR XBRL company facts · latest period ended 30 Jun 2026

BBIO earnings

SEC EDGAR
Date Period EPS Revenue
30 Jun 2026 Q2 2026 $-0.78 $244M
31 Mar 2026 Q1 2026 $-0.84 $195M
31 Dec 2025 FY 2025 $-3.78 $502M
30 Sep 2025 Q3 2025 $-0.95 $121M
30 Jun 2025 Q2 2025 $-0.95 $111M
31 Mar 2025 Q1 2025 $-0.88 $117M
31 Dec 2024 FY 2024 $-2.88 $222M
30 Sep 2024 Q3 2024 $-0.86 $3M

Next report no date announced in SEC filings yet

Reported figures & scheduled dates · SEC EDGAR filings

BBIO institutional holders

SEC Form 13F

14 of the 45 institutional funds we track reported a BBIO position for the quarter ended 30 Jun 2026 — a combined $2.0B; the latest of those filings landed 14 Aug 2026.

Fund Action Shares Value
Viking Global Investors Held (±25%) −16.0% shares 9,949,219 $741.0M
Two Sigma Investments Added +51.3% shares 4,722,185 $351.7M
Citadel Advisors Held (±25%) +18.5% shares 3,760,028 $280.0M
D. E. Shaw & Co. Added +42.7% shares 3,633,007 $270.6M
Point72 Asset Management New position 1,525,782 $113.6M
Balyasny Asset Management Added +251.3% shares 1,230,052 $91.6M
Renaissance Technologies Added +134.3% shares 856,846 $63.8M
Millennium Management Held (±25%) −23.0% shares 487,594 $36.3M
Bridgewater Associates Added +72.7% shares 448,143 $33.4M
Fisher Asset Management Held (±25%) −1.8% shares 345,351 $25.7M

Showing the 10 largest of 14 reported positions. The figures above count all of them.

Source: SEC EDGAR 13F filings

BBIO fails-to-deliver

SEC CNS data

On 28 Jul 2026, 10 shares of BBIO failed to deliver (about $841).

Settlement date Shares failed Notional % of shares out
28 Jul 2026 10 $841 <0.001%
24 Jul 2026 100 $8K <0.001%
23 Jul 2026 100 $8K <0.001%
22 Jul 2026 100 $8K <0.001%
20 Jul 2026 185 $15K <0.001%
17 Jul 2026 4 $321 <0.001%
08 Jul 2026 7,800 $608K 0.004%

Source: SEC fails-to-deliver (CNS) data

Congressional trades in BBIO

STOCK Act disclosures

The most recent congressional trade disclosed in BBIO is a purchase by Gilbert Ray Cisneros, Jr. (house, CA), dated 11 May 2026.

Date Member Type Amount
11 May 2026 filed 08 Jun 2026 Gilbert Ray Cisneros, Jr. house · Democrat–CA Purchase $1K–$15K
19 Mar 2026 filed 07 Apr 2026 Gilbert Ray Cisneros, Jr. house · Democrat–CA Purchase $1K–$15K

Source: U.S. House of Representatives financial disclosures